Helsinki HPV symposium 2016
On January 13th, 2016 the University of Tampere and Helsinki, the Karolinski Institute, and the Finnish Medical Association co-organised the 5th Helsinki HPV Workshop on Vaccinating Women and Men against Premature Death. The topic of the workshop was “from disease elimination to the elimination of oncogenic HPV” and many of the Coheahr consortium partners presented their work during this workshop.
The lectures can now be viewed online:
Elimination of HPV-associated cancers
Peter J.F. Snijders: HPV self-sampling
Pekka Nieminen: Screening of HPV vaccinated women
Xavier Bosch: Controlling cervical cancer in Europe
Silvia Franceschi: Elimination of cervical cancer from developing countries
Mark Jit: Cost-effectiveness of elimination of HPV-related cancers
Understanding the biology of prophylactic HPV vaccination
Margaret Stanley: Infection and vaccine induced HPV immune responses
Joakim Dilner: How do HPV vaccines protect?
Michael Pawlita: HPV-vaccine induced antibody response after 3, 2 and 1 dose
Elimination of major oncogenic HPV types
Matti Lehtinen: Community-randomized trial on the impact of different HPV vaccination strategies – An ancillary study on herd effect gained by gender-neutral strategy
David Mesher: Systematic review of studies on type-replacement
Iacopo Baussano: Elimination of HPV from different countries
Simopekka Vänskä: Impact of HPV elimination
Eduardo L. Franco: Risk Thresholds for Deciding When to Stop Screening in the Post-Vaccination Era
Helsinki HPV symposium 2012
On January 12th, 2012 the University of Tampere and Helsinki, the Family Federation Finland and the Finnish Medical Association co-organised the 4th Helsinki HPV Workshop on Vaccinating Women and Men against Premature Death. The topic of the workshop was “Human Papillomavirus vaccination: safety, sound efficacy and public health effectiveness” and many of the Coheahr consortium partners presented their earlier work (related to the PreHdict project) during this workshop.
A summary of the symposium was published in HPV Today, number 32/33, December 2014.
The lectures can be viewed online:
Safety of human papillomavirus at the population level
Daniel Weinberger (Harvard): Strain replacement following vaccination: the example of pneumococcus
Marko Merikukka (THL): No type-replacement following HPV vaccination
Sholom Wacholder (NCI): Safety of HPV vaccination based on adverse effect reporting
Jorma Paavonen (HUS): Safety of HPV vaccination compared to cervical screening
Efficacy of HPV vaccination against the most stringent end-points
Dan Apter (FFF): Efficacy of HPV vaccination in males
Kevin Ault (Emory): Efficacy of HPV vaccination against the stringent end-points
Allan Hildesheim (NCI): Choice of outcome for post-licensure HPV vaccine studies
Joakim Dillner (KI): Monitoring efficacy of HPV-vaccination
effectiveness and impact of different HPV vaccination and screening strategies
Marion Saville (Melbourne): Impact of 5-year school-based vaccination of early adolescents
Pekka Nieminen (HUS): Impact of organized primary HPV-screening
Iacopo Baussano (ICL/IARC): Modelling screening of HPV vaccinated birth cohorts
Matti Lehtinen (UTA): Assessing the effectiveness of different vaccination strategies
Lutz Gissmann (DKFZ): Human papillomavirus vaccines for developing countries
Marc Arbyn (WIV-ISP): Implementing HPV-disease control in the developing countries
Charite=Charite University, Berlin, DKFZ=Deutsches Krebsforschungsentrum, Emory=Emory University, FFF=Family Federation Finland, IARC=International Agency for Research on Cancer, ICL=Imperial College London, Harvard=Harvard University, KI=Karolinska Institute, McGill=McGill University Montreal, Melbourne=Victorian Cytology Service, Melbourne University, NCI=National Cancer Institute, WIV-ISP=Sceintific Institute of Public Health, Brussels
Press releases
Interview with dr Hans Berkhof on the website of the European Commission – Horizon 2020. 32.